Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP‐319 in pre‐clinical models of aggressive lymphomas
暂无分享,去创建一个
L. Cascione | A. Stathis | E. Gaudio | E. Zucca | M. Mascia | F. Bertoni | C. Tarantelli | S. Dirnhofer | M. Gerlach | F. Spriano | E. Bernasconi | Valdemar Priebe | A. Targa | V. Priebe
[1] L. Cascione,et al. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents , 2019, Haematologica.
[2] L. Cascione,et al. COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS , 2019, Hematological Oncology.
[3] M. Davids,et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. , 2019, The Lancet. Haematology.
[4] J. Kutok,et al. The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies , 2018, PloS one.
[5] S. O'brien,et al. Acalabrutinib combined with PI3Kδ inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies. , 2018 .
[6] Jennifer Yang,et al. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen , 2018, Leukemia & lymphoma.
[7] Michael L. Wang,et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial , 2017, The Lancet.
[8] E. Giné,et al. The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status , 2017, Haematologica.
[9] R. Ulrich,et al. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile , 2017, The Journal of Pharmacology and Experimental Therapeutics.
[10] D. Fabbro,et al. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy , 2017, Clinical Cancer Research.
[11] A. Kater,et al. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach , 2017, Haematologica.
[12] R. Ulrich,et al. Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model , 2017, Clinical Cancer Research.
[13] M. Introna,et al. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies , 2017, Haematologica.
[14] C. Flowers,et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. , 2017, Blood.
[15] C. Quéva,et al. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors , 2017, PloS one.
[16] M. Lange,et al. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT. , 2017, Cancer cell.
[17] M. Keating,et al. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells , 2016, Clinical Cancer Research.
[18] Lisa L. Smith,et al. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia , 2016, Clinical Cancer Research.
[19] J. Byrd,et al. Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma , 2016, PloS one.
[20] Jeffrey A Jones,et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.
[21] R. Pazdur,et al. FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia , 2015, Clinical Cancer Research.
[22] Roland Schmitz,et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.
[23] M. Kersten,et al. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. , 2015, Blood.
[24] Lei Nie,et al. FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma , 2015, Clinical Cancer Research.
[25] L. Cascione,et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs , 2015, Clinical Cancer Research.
[26] Xiaolin Hao,et al. Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease. , 2015, Journal of medicinal chemistry.
[27] L. Cascione,et al. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response , 2014, Oncotarget.
[28] Sam Michael,et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.
[29] Susan Wong,et al. First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3Kδ, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies , 2013 .
[30] L. Staudt,et al. Targeting pathological B cell receptor signalling in lymphoid malignancies , 2013, Nature Reviews Drug Discovery.
[31] M. Czuczman,et al. AMG 319, a Novel Inhibitor of Phosphoinositide-3 Kinase Delta (PI3Kd), Demonstrates Activity in Lymphoma Pre-Clinical Models , 2012 .
[32] D. Metz,et al. Phosphatidylinositol-3 Kinase Delta (PI3Kδ) Inhibitor AMG 319 Is a Potent, Selective and Orally Bioavailable Small Molecule Inhibitor That Suppresses PI3K-Mediated Signaling and Viability in Neoplastic B Cells , 2011 .
[33] Ting-Chao Chou,et al. Preclinical versus clinical drug combination studies , 2008, Leukemia & lymphoma.
[34] A. Markham,et al. Acalabrutinib: First Global Approval , 2017, Drugs.